474 related articles for article (PubMed ID: 29313389)
61. Summaries for patients. Stool DNA and occult blood testing to screen for colorectal neoplasia.
Ann Intern Med; 2008 Oct; 149(7):I20. PubMed ID: 18838720
[No Abstract] [Full Text] [Related]
62. Diagnostic accuracy of multitarget stool DNA testing for colorectal cancer screening: A systematic review and meta-analysis.
Dolatkhah R; Dastgiri S; Jafarabadi MA; Abdolahi HM; Somi MH
Gastroenterol Hepatol; 2022 Dec; 45(10):753-766. PubMed ID: 35101601
[TBL] [Abstract][Full Text] [Related]
63. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model.
Fisher DA; Saoud L; Hassmiller Lich K; Fendrick AM; Ozbay AB; Borah BJ; Matney M; Parton M; Limburg PJ
Cancer Med; 2021 Apr; 10(8):2855-2864. PubMed ID: 33314646
[TBL] [Abstract][Full Text] [Related]
64. Three-Year Interval for the Multi-Target Stool DNA Test for Colorectal Cancer Screening: A Longitudinal Study.
Imperiale TF; Lavin PT; Marti TN; Jakubowski D; Itzkowitz SH; May FP; Limburg PJ; Sweetser S; Daghestani A; Berger BM
Cancer Prev Res (Phila); 2023 Feb; 16(2):89-97. PubMed ID: 36205504
[TBL] [Abstract][Full Text] [Related]
65. The health economic impact of varying levels of adherence to colorectal screening on providers and payers.
Hathway JM; Miller-Wilson LA; Yao W; Jensen IS; Weinstein MC; Parks PD
J Med Econ; 2021; 24(1):69-78. PubMed ID: 33970747
[TBL] [Abstract][Full Text] [Related]
66. Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States.
Wang YR; Cangemi JR; Loftus EV; Picco MF
Am J Gastroenterol; 2013 Mar; 108(3):444-9. PubMed ID: 23295277
[TBL] [Abstract][Full Text] [Related]
67. DNA Methylation and Mutation of Small Colonic Neoplasms in Ulcerative Colitis and Crohn's Colitis: Implications for Surveillance.
Johnson DH; Taylor WR; Aboelsoud MM; Foote PH; Yab TC; Cao X; Smyrk TC; Loftus EV; Mahoney DW; Ahlquist DA; Kisiel JB
Inflamm Bowel Dis; 2016 Jul; 22(7):1559-67. PubMed ID: 27104828
[TBL] [Abstract][Full Text] [Related]
68. Clinical implications of low grade dysplasia found during inflammatory bowel disease surveillance: a retrospective study comparing chromoendoscopy and white-light endoscopy.
Ten Hove JR; Mooiweer E; van der Meulen de Jong AE; Dekker E; Ponsioen CY; Siersema PD; Oldenburg B
Endoscopy; 2017 Feb; 49(2):161-168. PubMed ID: 27951611
[No Abstract] [Full Text] [Related]
69. Comparison of Performance of Two Stool DNA Tests and a Fecal Immunochemical Test in Detecting Colorectal Neoplasm: A Multicenter Diagnostic Study.
Jin P; You P; Fang J; Kang Q; Gu F; Cai Y; Zhai H; Wang B; Li Y; Xu J; Wang J; He Y; Wang Y; Dai M; Sheng J
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):654-661. PubMed ID: 34933958
[TBL] [Abstract][Full Text] [Related]
70. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
[TBL] [Abstract][Full Text] [Related]
71. Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia.
Mu J; Huang Y; Cai S; Li Q; Song Y; Yuan Y; Zhang S; Zheng S
Clin Chim Acta; 2020 Feb; 501():42-47. PubMed ID: 31816287
[TBL] [Abstract][Full Text] [Related]
72. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia.
Tagore KS; Lawson MJ; Yucaitis JA; Gage R; Orr T; Shuber AP; Ross ME
Clin Colorectal Cancer; 2003 May; 3(1):47-53. PubMed ID: 12777192
[TBL] [Abstract][Full Text] [Related]
73. Performance improvements of stool-based screening tests.
van Dam L; Kuipers EJ; van Leerdam ME
Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):479-92. PubMed ID: 20833351
[TBL] [Abstract][Full Text] [Related]
74. Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study.
Gerrits MM; Chen M; Theeuwes M; van Dekken H; Sikkema M; Steyerberg EW; Lingsma HF; Siersema PD; Xia B; Kusters JG; van der Woude CJ; Kuipers EJ
Cell Oncol (Dordr); 2011 Apr; 34(2):107-17. PubMed ID: 21327897
[TBL] [Abstract][Full Text] [Related]
75. Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use.
Finney Rutten LJ; Parks PD; Weiser E; Fan C; Jacobson DJ; Jenkins GD; Zhu X; Griffin JM; Limburg PJ
Mayo Clin Proc; 2022 Jan; 97(1):101-109. PubMed ID: 34920895
[TBL] [Abstract][Full Text] [Related]
76. Inappropriate Ordering of Multitarget Stool DNA Tests for Colon Cancer Screening.
Ahn AB; Kulhari S; Rhee J; Cooper G
J Am Board Fam Med; 2024; 37(2):328-331. PubMed ID: 38740492
[TBL] [Abstract][Full Text] [Related]
77. Patients' perception of colonoscopy and acceptance of colonoscopy based IBD related colorectal cancer surveillance.
Braithwaite E; Carbonell J; Kane JS; Gracie D; Selinger CP
Expert Rev Gastroenterol Hepatol; 2021 Feb; 15(2):211-216. PubMed ID: 32981385
[TBL] [Abstract][Full Text] [Related]
78. A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy.
Haug U; Brenner H
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):422-8. PubMed ID: 15734968
[TBL] [Abstract][Full Text] [Related]
79. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening.
Imperiale TF; Porter K; Zella J; Gagrat ZD; Olson MC; Statz S; Garces J; Lavin PT; Aguilar H; Brinberg D; Berkelhammer C; Kisiel JB; Limburg PJ;
N Engl J Med; 2024 Mar; 390(11):984-993. PubMed ID: 38477986
[TBL] [Abstract][Full Text] [Related]
80. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort.
Miller-Wilson LA; Rutten LJF; Van Thomme J; Ozbay AB; Limburg PJ
Int J Colorectal Dis; 2021 Nov; 36(11):2471-2480. PubMed ID: 34019124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
